Pfizer's Trading Volume Surges 65% to $13.42 Billion Ranking 59th in Market Activity
1min read On March 31, 2025, Pfizer's trading volume reached $13.42 billion, marking a 65.45% increase from the previous day and ranking 59th in the day's stock market activity. The stock price of pfizer (PFE) rose by 0.52%, marking the second consecutive day of gains, with a total increase of 1.32% over the past two days.
Pfizer demonstrated robust operational efficiency and profitability potential, with a revenue growth of 21.90% and a return on equity (ROE) of 9.06%. The company reported revenues of $17.76 billion in the last reported quarter, representing a year-over-year change of +24.7%. EPS for the same period was $0.63, beating analysts' consensus estimates of $0.48 by $0.15.
Pfizer's strong financial performance and strategic developments have driven a buy rating. The company's non-COVID products saw a 12% operational revenue growth in FY 2024, highlighting its continued focus on commercial execution. Pfizer's market cap stands at $143 billion, reflecting its status as a huge global pharmaceutical company with a long-standing presence in the market.
Pfizer's future growth prospects are tied to its oncology portfolio and new product developments. The acquisition of Seagen has added many new oncology products, which are expected to grow by 14%, partially offsetting the decline in sales of COVID-19 vaccines. The company's strong pipeline and operational efficiency are key drivers for its future performance.
Ask Aime: What is the significance of Pfizer's strong financial performance and strategic developments in relation to its market position and future growth prospects?
